According to an article in The Australian, Nexpep will be starting their phase I study of a vaccine for Celiac Disease in April. Phase I trials are done to find out if the vaccine is safe. They will be enrolling 40 people in the study in Australia and following them over 11 months of therapy. If it proves to be safe, they will move on to a phase II trial in which they will examine if the vaccine is actually effective.
The vaccine is administered by injecting very small amounts of gluten peptides into a person and increasing the concentration over time. This is similar to the way allergy shots work; by desensitizing a person to the particular peptides so that over time they don't have a reaction when exposed to the environmental trigger (gluten).
Nexpep also has an interest in looking at this type of treatment for other autoimmune disorders such as diabetes and rheumatoid arthritis.
In related news, the Celiac Disease Awareness Campaign in their Winter 2009 newsletter reports that researchers in Great Britain have found several links between celiac disease and type-1 diabetes. The researchers found genetic markers linked to celiac disease that can also be associated with type-1 diabetes and factors linked to type-1 diabetes that can also be associated with increased risk for CD.